T1	intervention 0 9	Tamoxifen
T2	total-participants 473 478	13388
T4	outcome 1001 1043	reduced the risk of invasive breast cancer
T6	control 739 746	placebo
T7	control-participants 750 754	6707
T8	intervention-participants 782 786	6681
T11	cv-bin-abs 1133 1137	43.4
T12	iv-bin-abs 1145 1149	22.0
T13	outcome 1220 1234	decreased risk
T14	iv-bin-percent 1279 1282	44%
T15	iv-bin-percent 1298 1301	51%
T16	iv-bin-percent 1327 1330	55%
T17	iv-bin-percent 1409 1412	56%
T18	iv-bin-percent 1439 1442	86%
T19	outcome 1511 1556	reduced the risk of noninvasive breast cancer
T20	iv-bin-percent 1560 1563	50%
T21	outcome 1606 1653	occurrence of estrogen receptor-positive tumors
T22	iv-bin-percent 1657 1660	69%
T23	intervention-participants 1154 1158	1000
T3	eligibility 480 704	at increased risk for breast cancer because they 1) were 60 years of age or older, 2) were 35-59 years of age with a 5-year predicted risk for breast cancer of at least 1.66%, or 3) had a history of lobular carcinoma in situ
T5	outcome 1803 1833	rate of ischemic heart disease
T9	outcome 1859 1901	hip, radius (Colles'), and spine fractures
T10	outcome 1920 1946	rate of endometrial cancer
T24	outcome 2202 2227	endometrial cancer deaths
T25	outcome 2260 2328	liver cancers or increase in colon, rectal, ovarian, or other tumors
T26	outcome 2370 2431	rates of stroke, pulmonary embolism, and deep-vein thrombosis
T27	outcome 2565 2616	incidence of invasive and noninvasive breast cancer
